Chad Harman

CEO @Psycheceutical (OTCPK: $BWVI) | On a mission to radically advance mental health treatment.

[PSYCSpotlight @PSYC_Spot]

Topical Ketamine: A Game-Changer for #PTSD?

The cream targets NMDA receptors, like all ketamine administration routes. But it does so without entering the bloodstream.

https://t.co/lKUolxBZN3

[Psycheceutical @psycheceutical]

Our community crowdfunding campaign on @Wefunder is now live! Invest and be a part of our vision for the future of #mentalhealth treatment.

➡️ https://t.co/cyTaZjmrZB

[Chad Harman @ChadHarmanCEO]

It's an incredible honor to be nominated once again. So humbled and proud of the entire @Psycheceutical team! Thank you @MicrodoseHQ!

[Psycheceutical @psycheceutical]

The polls are open for @MicrodoseHQ's Third Annual Wonderland Awards, and we're thrilled to once again be nominated as B2B Tech Company of the Year! Help us win by voting once per day until November 3, and thank you for the continued incredible support!

https://t.co/MVf9596l5G

[Veterans Affairs @DeptVetAffairs]

:studio_microphone: Introducing the FIRST episode of "New Horizons in Health: Bringing Veteran Health Care into the Future"! Dr. Shereef Elnahal, VA Under Secretary for Health, explores the game-changing world of #psychedelic therapies for our #Veterans.
https://t.co/VYHFQO0UH6

[Psycheceutical @psycheceutical]

Join @ChadHarmanCEO tomorrow at 1PM ET in the #MarketMasters Room with @RagingBull for an exclusive interview and discussion about how @psycheceutical is bringing psychedelic medicines into the 21st century.

➡️ https://t.co/LcW7iwiDR7

$BWVI #mentalhealth #biotech

[Psycheceutical @psycheceutical]

Want to stay in the loop with the latest news, insights, and updates from the @Psycheceutical team? Be sure to join our community by signing up for our newsletter!

Subscribe Here: https://t.co/lqoMcsqmjk

$BWVI #biotech

[Chad Harman @ChadHarmanCEO]

Exciting news for @psycheceutical with the overall success of our first cohort from our Phase I clinical trial. Another strong milestone in our goal of bringing to market a novel method for treating #mentalhealth and neurodegenerative diseases. Keep an eye out for more progress!

[Psycheceutical @psycheceutical]

CLINICAL TRIAL UPDATE: We're excited to announce the completion of dosing of the first cohort of subjects in the Phase I clinical trial of our NeuroDirect™ topical ketamine formulation for the treatment of #PTSD.

The topical administration of NeuroDirect ketamine was shown to be safe and well-tolerated and with no clinically relevant adverse events or psychotomimetic effects seen, giving the Safety Review Committee confidence to proceed with an escalation of the dosage for the second cohort.

Explore the key results in our full announcement: https://t.co/TdGoYLa267

$BWVI #biotech #mentalhealth #neurodirect

[Chad Harman @ChadHarmanCEO]

This is an exciting day for everyone at @psycheceutical! We're looking forward to sharing more soon.

[Psycheceutical @psycheceutical]

We're pleased to announce that auditors RBSM LLP have completed a PCAOB audit of Psycheceutical's financial statements for the periods ending December 31, 2022 and 2021.

With the completion of this audit, Psycheceutical is well-positioned to focus on its near-term fundraising plans, to strategize its process and timing for becoming a fully reporting company with the Securities and Exchange Commission (SEC), and to advance its strategic plans for aligning its corporate name and listing symbol.

Read today's corporate update: https://t.co/ej4yp0m2mc

$BWVI #Biotechnology

[Psycheceutical @psycheceutical]

In a new study out of Finland, researchers found that the mechanism in psychedelics that causes antidepressant benefits is separate from the mechanism that causes hallucinations.

Read more from the study: https://t.co/XbfBzndoZ2

#mentalhealth #biotech #psychedelicmedicine

[Mugglehead Magazine @MuggleheadMag]

@psycheceutical has developed a ketamine topical that provides the benefits of the psychedelic without complications from psychoactive effects.

@MAPS Founder Rick Doblin said it was rare to come across a unique product like this.

#psychedelics

https://t.co/VukH0dMtho

[Zappy Zapolin @ZappyZapolin]

Great ongoing coverage for @psycheceutical $BWVI and its game-changing NeuroDirect™ technology!

Peace. Zappy

[Chad Harman @ChadHarmanCEO]

Very proud to share another major milestone in our upcoming clinical trials for NeuroDirect™ to treat #PTSD as we continue forward in Australia and begin first patient dosing in the coming weeks.

Many thanks to partners Cantheon Capital and iNGENu CRO for the continued support!

[Psycheceutical @psycheceutical]

We're excited to announce Psycheceutical $BWVI has secured funding for clinical trials of our NeuroDirect™ ketamine topical to treat #PTSD. With this support from Cantheon Capital, we move forward with two pivotal clinical trials in Australia.

https://t.co/NjkekvZcDX

[Psycheceutical @psycheceutical]

Senate Bill 58, introduced by Senator @Scott_Wiener, would allow people age 21 or older to own or prepare “certain hallucinogenic substances,” including psilocybin, psilocyn, dimethyltryptamine (DMT), ibogaine, and mescaline.

Read the full bill here: https://t.co/w8vrCCPS2v

[Psycheceutical @psycheceutical]

A @Gallup survey published this week found 29% of U.S. adults report being diagnosed with #depression at some point during their lives, up from 19.6% in 2015 — the highest rate recorded since it began tracking depression rates. #mentalhealthawareness

https://t.co/F8kLTcWt14

[Psycheceutical @psycheceutical]

As #mentalhealth struggles rise, the demand for innovative solutions is more pressing than ever.

Read the latest coverage in @Benzinga to learn more about how @Psycheceutical's next-gen NeuroDirect™ topical delivery system could offer promising results.

https://t.co/n8wvykoJSj

[Zappy Zapolin @ZappyZapolin]

Psycheceutical’s (BWVI) patents for delivering any psychedelic compound, in a topical cream applied at the back of the neck, base of the hairline, eliminates the psychedelic effect, while still providing the healing, and neurogenesis patients are seeking, is in my opinion the biggest breakthrough in mental health treatment ever!
Peace. Zappy

[PSYCSpotlight @PSYC_Spot]

Blowing The Mind of @MAPS Founder And Famed #Psychedelic Industry Leader @RickDoblin

Rick Doblin was surprised with a new technology being developed by @psycheceutical: a topical cream called NeuroDirect™ which potentially allows for a safer delivery.

https://t.co/c478WdWpTx

[Zappy Zapolin @ZappyZapolin]

I had the pleasure recently of blowing the mind of Rick Doblin, “the godfather of the psychedelic industry". How? @Psycheceutical's NeuroDirect™ Topical Cream for PTSD - a total gamechanger.

Peace. Zappy

https://t.co/ujAENEZLam

[Psycheceutical @psycheceutical]

Expand your mind & be part of the future of mental health with Psycheceutical's @ZappyZapolin and @KaiaRoman, speaking at this year's @Benzinga Psychedelics Capital Conference on April 13. ⁠
⁠
Save 20% on tickets with our code, "PSYCHECEUTICAL20" - https://t.co/kcV4Bq6TBB

[Zappy Zapolin @ZappyZapolin]

Excited to again be speaking at the @Benzinga Psychedelics Capital Conference in Miami Beach on April 13! ⁠ If you've want to be a part of the future of modern medicine, this is one event you cannot miss.⁠

Tickets: https://t.co/JBK606OluY
⁠
Peace. Zappy